logo

Protalix Biotherapeutics Inc. (PLX)



Trade PLX now with
  Date
  Headline
10/17/2019 7:48:58 AM Protalix Says Positive 12-Month Interim Data From BRIDGE Phase III Open Label Switch-over Study Of Pegunigalsidase Alfa
9/24/2019 7:04:41 AM Protalix BioTherapeutics And Chiesi Group Complete Enrollment In The Third Phase III Clinical Trial Of PRX-102
8/8/2019 6:15:54 AM Protalix BioTherapeutics H1 Net Loss $15.0 Mln Or $0.10/Shr Vs Loss Of $15.7 Mln Or $0.11/Shr Last Year
7/29/2019 7:12:33 AM Protalix BioTherapeutics Appoints Eyal Rubin SVP And CFO
6/27/2019 1:06:57 AM Plexure Unveils AI Driven Analytics Studio
6/17/2019 7:11:00 AM Protalix BioTherapeutics Completes Enrollment In Phase III BRIGHT Clinical Trial Of PRX 102 For Fabry Disease
3/18/2019 6:57:21 AM Protalix FY Net Loss $26.5 Mln Or $0.18 Per Share
1/28/2019 7:03:57 AM Protalix BioTherapeutics To Present Preliminary Data From The BRIGHT Study Of Pegunigalsidase Alfa For Fabry Disease
12/17/2018 7:01:33 AM Protalix BioTherapeutics Completes Enrollment In Phase III BRIDGE Clinical Trial Of Pegunigalsidase Alfa
11/7/2018 7:01:07 AM Protalix BioTherapeutics Q3 Loss Per Share $0.10 Vs Loss $0.09 Last Year
10/5/2018 7:18:36 AM Protalix BioTherapeutics Presents Positive Preliminary Data From BRIDGE Study Of Pegunigalsidase Alfa
9/21/2018 10:58:57 AM Protalix Reports Positive Preliminary Data From BRIDGE Study Of Pegunigalsidase Alfa For Treatment Of Fabry Disease
  
 
>